Breaking News Instant updates and real-time market news.

BLUE

bluebird bio

$60.35

-4.05 (-6.29%)

07:12
12/01/16
12/01
07:12
12/01/16
07:12

bluebird bio data positive, says Wells Fargo

After bluebird bio announced interim Phase 1 dose escalation data for its CAR T product bb2121 in patients with relapsed/refractory multiple myeloma, Wells Fargo says the data shows that the product provides "a profound benefit for patients exhausting available treatment options." Wells thinks that the product could be approved on an accelerated timetable, and it keeps an Outperform rating on the stock.

  • 01

    Dec

  • 01

    Dec

  • 03

    Dec

  • 03

    Dec

BLUE bluebird bio
$60.35

-4.05 (-6.29%)

11/23/16
JANY
11/23/16
NO CHANGE
JANY
Weakness in bluebird bio unwarranted after Juno trial halt, says Janney Capital
11/23/16
11/23/16
NO CHANGE

Buy
bluebird bio weakness unwarranted after Juno trial halt, says Janney Capital
As previously reported, Janney Capital analyst Debjit Chattopadhyay said the weakness in bluebird bio (BLUE) is unwarranted on the heels of Juno's (JUNO) second clinical hold for JCAR015. Chattopadhyay notes several key differences between JCAR015 and bluebird's bb2121, including their targets, diseases, vectors, preconditioning regimens and others. He remains a buyer of bluebird ahead of a "potentially watershed ASH for its lentiglobin platform" and keeps a Buy rating on the stock.
11/23/16
PIPR
11/23/16
NO CHANGE
PIPR
Piper says CAR-T researchers must heed risks highlighted by Juno news
Piper Jaffray analyst Joshua Schimmer said the CAR-T field has "taken another step back" after Juno Therapeutics (JUNO) put a hold on its JCAR015 trial again due to fatal cerebral edema and cautioned companies exploring these therapies to be mindful of "unnecessarily aggressive development and under-appreciation of the potent and possibly highly toxic nature" of the approach. However, Schimmer expressed his confidence that companies he covers in the CAR-T space - namely bluebird bio (BLUE), Cellectis (CLLS), Celgene (CELG), Bellicum Pharmaceuticals (BLCM), Lion Biotechnologies (LBIO) and NantKwest (NK) - will "respect the power of these platforms and remember patients' lives are more important than stock prices."
11/29/16
PIPR
11/29/16
NO CHANGE
PIPR
Piper sees bluebird regaining 'mojo and momentum'
After hosting management for an investor dinner, Piper Jaffray analyst Joshua Schimmer sees bluebird bio regaining its "mojo and momentum." The analyst expects a "steady stream of positive updates and derisking" starting with BCMA CAR-T data update this week and extending into optimizing LentiGlobin's profile for sickle cell and betathal in 2017. Schimmer has an Overweight rating on bluebird shares with a $95 price target. The biotechnology company closed yesterday down 5% to $60.65.

TODAY'S FREE FLY STORIES

CCXI

ChemoCentryx

$8.31

-0.04 (-0.48%)

17:01
01/22/18
01/22
17:01
01/22/18
17:01
Hot Stocks
ChemoCentryx reports 'positive' survival results from CCX872 trial »

ChemoCentryx announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NWHM

New Home Company

$12.89

0.01 (0.08%)

16:58
01/22/18
01/22
16:58
01/22/18
16:58
Syndicate
Breaking Syndicate news story on New Home Company »

New Home Company files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

NWHM

New Home Company

$12.89

0.01 (0.08%)

16:58
01/22/18
01/22
16:58
01/22/18
16:58
Syndicate
Breaking Syndicate news story on New Home Company »

New Home Company files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

TROW

T. Rowe Price

$117.40

0.05 (0.04%)

16:57
01/22/18
01/22
16:57
01/22/18
16:57
Hot Stocks
T. Rowe Price sees FY18 effective tax rate 24%-27% »

On December 22, 2017, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICE

IntercontinentalExchange

$75.83

0.23 (0.30%)

16:45
01/22/18
01/22
16:45
01/22/18
16:45
Hot Stocks
Natixis, NYSE enter licensing agreement »

Natixis Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBIO

Catalyst Biosciences

$21.21

1.72 (8.83%)

16:43
01/22/18
01/22
16:43
01/22/18
16:43
Syndicate
Breaking Syndicate news story on Catalyst Biosciences »

Catalyst Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRET

Investors Real Estate

$5.74

0.03 (0.53%)

16:40
01/22/18
01/22
16:40
01/22/18
16:40
Hot Stocks
Investors Real Estate completes sale of two additional medical office buildings »

IRET completed the sale…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FFIC

Flushing Financial

$28.93

-0.1 (-0.34%)

16:39
01/22/18
01/22
16:39
01/22/18
16:39
Hot Stocks
Flushing Financial announces dividend plans for 2018 »

Flushing Financia, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

JMBA

Jamba

$9.14

-0.01 (-0.11%)

16:37
01/22/18
01/22
16:37
01/22/18
16:37
Syndicate
Jamba 2.1M share Block Trade; price range $8.25-$8.40 »

Morgan Stanley is acting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FULT

Fulton Financial

$18.65

0.1 (0.54%)

16:37
01/22/18
01/22
16:37
01/22/18
16:37
Earnings
Fulton Financial reports Q4 EPS 19c, consensus 28c »

Net interest income for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

AMGN

Amgen

$192.33

3.05 (1.61%)

16:36
01/22/18
01/22
16:36
01/22/18
16:36
Hot Stocks
Amgen: Aimovig met all primary, secondary endpoints in Phase 3b LIBERTY study »

Amgen announced positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 03

    Feb

  • 16

    Feb

  • 08

    Mar

  • 25

    Mar

  • 23

    Apr

  • 30

    Apr

  • 17

    May

  • 28

    May

AMGN

Amgen

$192.33

3.05 (1.61%)

16:34
01/22/18
01/22
16:34
01/22/18
16:34
Hot Stocks
Breaking Hot Stocks news story on Amgen »

Amgen: Aimovig met all…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 03

    Feb

  • 16

    Feb

  • 08

    Mar

  • 25

    Mar

  • 23

    Apr

  • 30

    Apr

  • 17

    May

  • 28

    May

FL

Foot Locker

$50.37

0.16 (0.32%)

16:32
01/22/18
01/22
16:32
01/22/18
16:32
Hot Stocks
Foot Locker makes strategic investment in Carbon38 »

Foot Locker announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPE

EP Energy

$2.48

0.17 (7.36%)

16:32
01/22/18
01/22
16:32
01/22/18
16:32
Hot Stocks
EP Energy sees FY18 $600M-$650M of oil and gas expenditures, »

Sees FY18 81…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRI

Darden

$98.06

-0.98 (-0.99%)

16:31
01/22/18
01/22
16:31
01/22/18
16:31
Hot Stocks
Darden names Dave George as COO »

Darden Restaurants…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RAD

Rite Aid

$2.29

-0.02 (-0.87%)

, WBA

Walgreens Boots Alliance

$77.40

0.93 (1.22%)

16:31
01/22/18
01/22
16:31
01/22/18
16:31
Hot Stocks
Rite Aid provides update on sale of assets to Walgreens Boots Alliance »

Rite Aid Corporation…

RAD

Rite Aid

$2.29

-0.02 (-0.87%)

WBA

Walgreens Boots Alliance

$77.40

0.93 (1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZION

Zions Bancorp

$54.16

0.43 (0.80%)

16:30
01/22/18
01/22
16:30
01/22/18
16:30
Earnings
Zions Bancorp reports Q4 adjusted EPS 80c, consensus 73c »

Harris H. Simmons,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

EPE

EP Energy

$2.48

0.17 (7.36%)

16:30
01/22/18
01/22
16:30
01/22/18
16:30
Hot Stocks
EP Energy reports preliminary FY17 production results of 82,300MBoe/d »

Preliminary FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
01/22/18
01/22
16:30
01/22/18
16:30
Options
Preliminary option volume of 20.3M today »

Preliminary option volume…

RMD

ResMed

$87.51

-1.17 (-1.32%)

16:30
01/22/18
01/22
16:30
01/22/18
16:30
Hot Stocks
Breaking Hot Stocks news story on ResMed »

ResMed up 8.5% to $95.00…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

EMR

Emerson

$73.26

0.12 (0.16%)

16:29
01/22/18
01/22
16:29
01/22/18
16:29
Initiation
Emerson initiated  »

Emerson initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

JUNO

Juno Therapeutics

$86.00

18.19 (26.83%)

, CELG

Celgene

$102.91

0.26 (0.25%)

16:28
01/22/18
01/22
16:28
01/22/18
16:28
Downgrade
Juno Therapeutics, Celgene rating change  »

Juno Therapeutics…

JUNO

Juno Therapeutics

$86.00

18.19 (26.83%)

CELG

Celgene

$102.91

0.26 (0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

HSGX

Histogenics

16:28
01/22/18
01/22
16:28
01/22/18
16:28
Syndicate
Breaking Syndicate news story on Histogenics »

Histogenics files $50M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

TD

Toronto-Dominion

$59.72

0.47 (0.79%)

, AMTD

TD Ameritrade

$55.88

0.71 (1.29%)

16:27
01/22/18
01/22
16:27
01/22/18
16:27
Hot Stocks
TD Bank Group comments on expected impact of TD Ameritrade's Q1 earnings »

TD Bank Group (TD)…

TD

Toronto-Dominion

$59.72

0.47 (0.79%)

AMTD

TD Ameritrade

$55.88

0.71 (1.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 16

    Feb

VR

Validus

$67.29

20.57 (44.03%)

, AIG

AIG

$61.00

-0.55 (-0.89%)

16:26
01/22/18
01/22
16:26
01/22/18
16:26
Downgrade
Validus, AIG rating change  »

Validus downgraded to…

VR

Validus

$67.29

20.57 (44.03%)

AIG

AIG

$61.00

-0.55 (-0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

  • 09

    Feb

  • 20

    Feb

  • 21

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.